

February 09, 2026

To,
Listing/ Compliance Department
BSE LTD.
Pheroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Outcome of Board Meeting
Ref: Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

We wish to inform you that the Board of Directors at their meeting held today i.e. **Monday, February 09, 2026** inter-alia considered and approved the following:

- Unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025, basis recommendation of the Audit Committee;
- Auditor's Report on the Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025;
- Declaration of Interim Dividend of ₹1.5/- (@ 30%) per Equity Share of ₹5/- each for the Financial Year 2025-26.

Further, please note that as per the Regulation 42(1)(a) of the SEBI (LODR) Regulations, 2015, Monday, February 16, 2026 has been fixed as 'Record Date' for the purpose of payment of Interim Dividend.

The meeting of the Board of Directors commenced at 2:00 p.m. and concluded at 07:00 p.m.

The above information is also available on the website of the Company: www.aartipharmalabs.com

Please take the same on your records.

Thanking you,

Yours faithfully,
For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR
COMPANY SECRETARY AND LEGAL HEAD
ICSI M. NO. A22565

Encl: a/a

AARTI PHARMA LABS LIMITED

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(Amount Rs in lakhs except EPS)

Notes

NOTES

- 1 The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 2 The above results for the Quarter and Nine months ended ended December 2025, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on **9th February, 2026**.
- 3 The above results does not include Revenue of Rs 4,935 lakhs in respect of Goods Shipped in Q3 FY26 but being in-transit and not reaching the agreed place of delivery by the cut-off date i.e. 31-Dec-2025.
The same is included as 'Stock in Transit' at a valuation of Rs 3,015 Lakhs. The goods have reached the destination in Q4.
- 4 The Government of India notified the new labour codes on November 21, 2025. Accordingly, the Company has assessed the impact of these changes, and, based on available information, estimates and an actuarial valuation, has made an incremental provision of Rs. 279.49 Lakhs for the impact of new labour codes under exceptional items head in the above Financial Results for the quarter and nine months ended on December 31, 2025.
- 5 The Board of Directors at its meeting held on **9th February 2026**, has declared an interim dividend of Rs. 1.50/- (30%) per equity shares of Rs5/each.
- 6 The Company has identified only one segment i.e. Pharmeceuticals.
- 7 The aforesaid financial results are available on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com
- 8 Figures for the previous period have been regrouped or rearranged wherever necessary

Place : Mumbai

Date : 9th Februry, 2026



For AARTI PHARMA LABS LIMITED

H. H. G. S. G. 1

Vice Chairperson & Managing Director

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA. **T :** +91 22 67976666 | **F :** +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Independent Auditors' Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Aarti Pharmalabs Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended.

To

The Board of Directors of Aarti Pharmalabs Limited


1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Aarti Pharmalabs Limited** ("the Company") for the quarter and nine months period ended 31st December 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. Emphasis of Matter

We draw attention to note 3 to the standalone financial results, which describe the treatment as per the requirement of Ind AS for an export transaction that has taken place in cut-off period. Our conclusion is not modified in respect of this matter.

For Gokhale & Sathe
Chartered Accountants
Firm Registration No.: 103264W



Uday Girjapure
Partner
Membership Number - 161776
UDIN: 26161776VMEUKA5262

Place: Mumbai
Date: February 09, 2026

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 ST DECEMBER, 2025 (Amount Rs in lakhs except EPS)							
Sr. No.	Particulars	CONSOLIDATED RESULTS					
		3 Months Ended		9 Year Ended		Year Ended	
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Audited)	31-12-2025 (Unaudited)	31-12-2024 (Audited)	31st March 2025 (Audited)
1	INCOME						
	a) Revenue from Operations (Net)	43,227.27	41,833.48	53,777.82	123,679.85	155,129.75	211,507.45
	b) Other Income	(37.12)	5.03	502.77	127.46	1,172.67	1,011.92
	Total Income	43,190.15	41,838.51	54,280.59	123,807.31	156,302.42	212,519.38
2	EXPENSES						
	a) Cost of Materials Consumed	20,941.62	20,346.47	24,729.95	60,430.29	70,157.20	83,579.81
	b) Purchases of Stock-in-Trade	213.77	2,326.13	786.57	4,722.18	19,290.63	17,663.47
	c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(3,889.82)	(1,694.98)	625.30	(9,971.40)	(4,535.26)	6,422.04
	d) Employee Benefits Expense	4,337.79	4,341.22	4,163.07	12,804.69	11,859.41	16,195.95
	e) Finance Costs	1,257.96	1,066.52	997.44	3,003.97	2,031.31	2,689.64
	f) Depreciation and Amortisation Expenses	2,861.77	2,476.92	2,303.75	7,617.91	6,408.82	8,690.40
	g) Other Expenses	11,393.07	9,042.77	10,611.97	28,464.48	26,483.34	41,209.14
	Total Expenses	37,116.17	37,905.04	44,218.03	107,072.11	131,695.45	176,450.44
3	Profit before share of profit/(loss) of exceptional items, joint ventures and tax (1-2)	6,073.98	3,933.46	10,062.56	16,735.20	24,606.98	36,068.93
4	Exceptional Items (Net of Tax Expense)	279.49			279.49		-
5	Profit before share of profit/(loss) of joint ventures, and tax (3-4)	5,794.49	3,933.46	10,062.56	16,455.71	24,606.98	36,068.93
6	Share of profit/(loss) of joint ventures	492.39	(64.25)	-	248.53	-	-
7	Profit/(Loss) before Tax (5-6)	6,286.88	3,869.22	10,062.56	16,704.24	24,606.98	36,068.93
8	TAX EXPENSES						
	a) Current Year Tax	928.68	220.00	2,198.12	2,410.68	5,059.27	7,220.26
	b) Earlier Year Tax	562.64	856.91	465.64	1,752.89	-	(469.52)
	c) Deferred Tax					1,141.31	2,077.74
	Total Tax Expenses	1,491.32	1,076.91	2,663.77	4,163.57	6,200.59	8,828.47
9	Net Profit/(loss) for the period (7-8)	4,795.56	2,792.31	7,398.79	12,540.67	18,406.39	27,240.46
	Profit/(loss) for the period attributable to						
	a) Owners of the Company	4,795.56	2,792.31	7,398.79	12,540.67	18,406.39	27,240.46
	b) Non Controlling Interest	-	-	-	-	-	-
10	OTHER COMPREHENSIVE INCOME (Net of Tax)						
	a. Items that will be reclassified to Statement of Profit and Loss	(163.72)	(165.30)		(228.34)	(389.45)	(975.73)
	b. Items that will not be reclassified to Statement of Profit and Loss	7.35	88.13	(270.83)	91.42	(109.82)	
	Other comprehensive income / (loss) for the year, net of tax	(156.37)	(77.18)	(270.83)	(136.92)	(499.27)	(975.73)
11	Total Comprehensive Income for the period (9+10)	4,639.19	2,715.14	7,127.96	12,403.74	17,907.12	26,264.73
	Profit/(loss) for the period attributable to						
	a) Owners of the Company	4,639.19	2,715.14	7,127.96	12,403.74	17,907.12	26,264.73
	b) Non Controlling Interest	-	-	-	-	-	-
12	Earnings per Equity share: - (Rs)						
	(1) Basic	5.29	3.08	8.16	13.84	20.31	30.06
	(2) Diluted	5.29	3.08	8.16	13.82	20.30	30.04
13	Paid-up Equity Share Capital (Face Value of Rs. 5/-each)	4,532.36	4,532.06	4,531.30	4,532.36	4,531.30	4,531.73
	Reserve excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year						194,458.91
	Notes						
1	The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).						
2	The above results for the Quarter and Nine months ended December 2025, have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 9th February, 2026						
3	As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polchem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.						
4	The above results do not include Revenue of Rs 4,935 lakhs in respect of Goods Shipped in Q3 FY26 but being in-transit and not reaching the agreed place of delivery by the cut-off date i.e. 31-Dec-2025. The same is included as 'Stock in Transit' at a valuation of Rs 3,015 Lakhs. The goods have reached the destination in Q4.						
5	The Government of India notified the new labour codes on November 21, 2025. Accordingly, the Company has assessed the impact of these changes, and, based on available information, estimates and an actuarial valuation, has made an incremental provision of Rs. 279.49 Lakhs for the impact of new labour codes under exceptional items head in the above Financial Results for the quarter and nine months ended on December 31, 2025.						
6	The Board of Directors at its meeting held on 9th February 2026, has declared an interim dividend of Rs. 1.50/- (30%) per equity shares of Rs5/each.						
7	The Company has identified only one segment i.e. Pharmaceuticals.						
8	The aforesaid financial results are available on the Company's website at www.aartipharmalabs.com and are also available on the website of BSE limited www.bseindia.com & the National Stock Exchange of India Limited www.nseindia.com						
9	Figures for the previous period have been regrouped or rearranged wherever necessary						



Place : Mumbai
Date : 9th February, 2026



For AARTI PHARMALABS LIMITED


Hetal Gogri Gala
Vice Chairperson & Managing Director

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234

Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655

Independent Auditors' Limited Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Aarti Pharmalabs Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended.

To

The Board of Directors of
Aarti Pharmalabs Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results ("the Statement") of **Aarti Pharmalabs Limited** ("the Parent"), (the Parent, its subsidiaries and joint ventures together referred as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its joint ventures for the quarter and nine months period ended 31st December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ("the Regulation") as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated 29th March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

- a. **Subsidiaries**
 - i. Aarti USA Inc
 - ii. Aarti Pharmachem Ltd.
- b. **Joint Venture**
 - i. Ganesh Polychem Limited (w.e.f. 1st April 2025)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of audit reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Emphasis of Matter

We draw attention to note 4 to the consolidated financial results, which describe the treatment as per the requirement of Ind AS for an export transaction that has taken place in cut-off period. Our conclusion is not modified in respect of this matter.

7. Other Matter

The accompanying Statement includes the audited interim standalone financial results/financial information in respect of:

(a) Subsidiaries:

One domestic subsidiary whose financial results reflect total revenue from operations of Rs. NIL and Rs. NIL, total net loss after tax of Rs. 0.15 Lakhs and Rs. 0.32 Lakhs and total comprehensive income of Rs. 0.15 Lakhs and Rs. 0.32 Lakhs for the quarter and nine months period ended December 31, 2025 respectively, as considered in the consolidated financial results, which have been audited by their respective independent auditors.

(b) Joint Venture:

The Group's share of profit/loss in one joint venture, Ganesh Polychem Limited (consolidated w.e.f. 1st April 2025), whose total net profit after tax was Rs. 492.38 Lakhs and Rs. 248.53 Lakhs (share of profit) and total comprehensive income was Rs. 437.27 Lakhs and Rs. 202.21 Lakhs (share of profit) for the quarter and nine months period ended December 31, 2025 respectively, as considered in the consolidated financial results, which have been reviewed by their respective independent auditors.

The independent auditors' reports on Financial Results of these entities have been furnished to us and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of these matters.

8. Other Matter - Unaudited Foreign Subsidiary

The accompanying Statement includes the unaudited interim standalone financial results/financial information in respect of:

One foreign subsidiary whose unaudited interim standalone financial results/financial information reflect total revenue from operations of Rs. 205.22 Lakhs and Rs. 1,638.80 Lakhs, total net loss after tax of



Rs. 81.12 Lakhs and Rs. 59.32 Lakhs and total comprehensive income of Rs. (245.39) Lakhs and Rs. 106.68 Lakhs for the quarter and nine months period ended December 31, 2025 respectively, as considered in the Statement.

This unaudited interim standalone financial result has not been reviewed by an auditor and was provided by Management. Our conclusion regarding the amounts and disclosures for this subsidiary is based solely on this unaudited information. Management has represented that this interim result is not material to the Group.

Our conclusion is not modified in respect of this matter.

For Gokhale & Sathe
Chartered Accountants
Firm Registration No.: 103264W

307



Uday Girjapure
Partner
Membership Number - 161776
UDIN: 26161776KLHPAR9772
Place: Mumbai
Date: February 09, 2026